Clariant Chemicals Net Profit Falls By 39% On Yearly Basis
Nutan Gupta / 06 May 2014

Clariant Chemicals announced its financial results for the three-month period ended 31 March, 2014. The company booked profit in this quarter as compared to the loss of Rs 6.1 crore in the previous quarter ended 31 December, 2013.
Clariant Chemicals, which is among one of India's leading specialty chemicals companies has posted better financial results for the quarter ending 31 March, 2014. The total income from operations for the company came in at Rs 284.68 crore in the current quarter as compared to Rs 284.57 crore in the corresponding quarter last year. The total expenses of the company stood at Rs 267.10 crore as against Rs 253.68 crore in the same quarter previous year. The total expenses included the cost of materials consumed of Rs 145.57 crore.
The finance costs of the company, however, came down to Rs 19 lakh in the current quarter from Rs 73 lakh in the same quarter last year. The company posted profit of Rs 15.13 crore in this quarter as against a loss of Rs 6.1 crore in the last quarter (ended 31 December, 2013). However, the net profit went down by 39% if we compare it on an yearly basis.
Coming to the segment-wise revenue, of the total sale of Rs 274.21 crore, Rs 145.42 crore came in from the Pigments and Colors business, while Rs 128.79 crore came in from Dyes and Specialty Chemicals business.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.